Novartis headquarters

5. Fevipiprant

Novartis’ second entry on the list is fevipiprant, an orally active prostaglandin DP2 receptor antagonist which failed to improve lung function in two phase 3 trials involving patients with allergic asthma. It had previously been billed as another of Novartis’ blockbuster contenders.